Monte Rosa Therapeutics, Inc. (GLUE)
NASDAQ: GLUE · Real-Time Price · USD
17.66
-0.14 (-0.79%)
At close: Mar 9, 2026, 4:00 PM EDT
18.01
+0.35 (1.98%)
After-hours: Mar 9, 2026, 4:12 PM EDT
Monte Rosa Therapeutics Revenue
Monte Rosa Therapeutics had revenue of $12.77M in the quarter ending September 30, 2025, with 38.54% growth. This brings the company's revenue in the last twelve months to $181.54M, up 1,112.27% year-over-year. In the year 2024, Monte Rosa Therapeutics had annual revenue of $75.62M.
Revenue (ttm)
$181.54M
Revenue Growth
+1,112.27%
P/S Ratio
7.70
Revenue / Employee
$1,234,952
Employees
147
Market Cap
1.40B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 75.62M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionGLUE News
- 13 days ago - Monte Rosa Therapeutics Presents Updated Clinical Data from Phase 1/2 Study of MRT-2359 in Combination with Enzalutamide in Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer Patients at ASCO Genitourinary Cancers Symposium (ASCO GU) - GlobeNewsWire
- 14 days ago - Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - Monte Rosa Therapeutics Announces Pricing of $300 Million Underwritten Public Offering - GlobeNewsWire
- 2 months ago - Monte Rosa Therapeutics: Competitive MRT-8102 Results Offer Additional Platform Validation - Seeking Alpha
- 2 months ago - Monte Rosa Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants - GlobeNewsWire
- 2 months ago - Monte Rosa Therapeutics Announces Positive Interim Phase 1 Data of MRT-8102 Demonstrating Profound CRP Reductions in Elevated CVD-risk Subjects - GlobeNewsWire
- 2 months ago - Monte Rosa Therapeutics to Present Interim MRT-8102 Phase 1 Study Results - GlobeNewsWire
- 2 months ago - Why Is Monte Rosa Stock Trading Higher Today? - Benzinga